Learn about Alice Shaw, MD, PhD, Massachusetts General Hospital
Alice T. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School. She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr. Tyler Jacks at MIT.
In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research. Her clinical research focuses on a variety of different molecularly-defined subsets of non-small cell lung cancer (NSCLC). Her translational research focuses on elucidating mechanisms of resistance to targeted therapies. Based on her research, she has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, and her current efforts focus on developing novel combinatorial strategies aimed at overcoming drug resistance.
Dr. Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Wellcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, SU2C/AACR/ACS, and the NIH/NCI. In 2014 she was elected as a member to the American Society of Clinical Investigation. She is a standing member of the FDA Oncologic Drugs Advisory Committee and she recently joined the LUNGevity Foundation Scientific Advisory Board.
Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017
Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center
See below for our growing list of topics and presenters!
|8:30 – 10:00 am
|The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
|10:30 – noon
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West
1:00 – 2:30 pm
Presentations by Lung Cancer Sub-type *Available treatment options *Acquired resistance: How do you pick your next treatment?
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient
2:50 – 4:00 pm
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger
Please feel free to offer comments and raise questions in our Discussion Forums.
GRACE would like to thank the following companies for their support of this forum:
Hi Oaktowngrrl, Welcome to Grace. I'm so sorry you're going through this.
Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...
Hello Hello, Just want to let you know I see your post and will respond more appropriately in the morning.
I'm sure you're…